ensysce.com (ENSC) - Market Cap to Net Income

Ensysce Biosciences, Inc. - graphic logo of issuer ENSC

Ensysce Biosciences operates as a virtual biopharma business, fully outsourcing synthesis and testing to third-party contractors. Simultaneously, Ensysce Biosciences collaborates with scientific centers to develop overdose protection systems for analgesics. This chart on GURU.Markets demonstrates the -0.60 indicator. Asset stability is supported by the innovative TAAP technology and FDA government support within the fight against the opioid crisis, which retains institutional investors.

ensysce.com (ENSC): Price to Earnings Ratio from 07/04/2022 to 11/10/2026

Comprehensive metric breakdowns and analytics for Ensysce Biosciences Inc. (ENSC)

- share price and expert price forecast:
Price Performance Chart Ensysce|ENSC - Analyst Consensus Forecast
- market capitalization indicators:
Market Valuation Ensysce Biosciences, Inc.|ENSC - Enterprise Value
- business book valuation details:
Book Value per Share Ensysce Biosciences|ENSC - Company Book Value|Market Value to Book Value ensysce.com|ENSC - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Ensysce Biosciences|ENSC - Long-Term Debt to Capital|Current Liabilities to Capital Ensysce|ENSC - Company Debts|Debt to Book Value Ratio Ensysce Biosciences, Inc.|ENSC - Company Long-Term Debt|Short-Term Debt Volume Ensysce Biosciences|Immediate Liquidity ensysce.com
- net income and valuation ratios data:
ENSC - Company Net Income|Company Profit Forecast Ensysce Biosciences|ENSC - P/E Multiple|Projected Price to Earnings Ensysce|ENSC - PEG Multiple|Company Value to EBITDA Ensysce Biosciences, Inc.|ENSC - Operating profit before deduction of amortization|Earnings per share for the trailing year Ensysce Biosciences|ENSC - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ensysce.com|ENSC - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Ensysce Biosciences
Comprehensive company analysis:ensysce.com ENSC
Signature product of Ensysce Biosciences, Inc.

Ensysce Biosciences is developing innovative pain management platforms, where market valuation depends on the success of clinical trials. The company's current price-to-earnings ratio stands at -0.60, reflecting market expectations for future cash flows. This ratio measures the price of a single share relative to net income, determining the investment payback period. For a biotech firm with limited runway, this indicator often becomes a formality, as the price is driven by Phase 2 potential. The asset's fundamental attractiveness is now determined by the balance between liquidity risks and upcoming catalysts.

Analysis of competing companies

INDV: Company Value to Net Income|P/E Multiple COLL|CRON: Market Cap to Net Income|P/E Multiple CGC (Tweed)|P/E Multiple Canna Cabana HITI|ACB - Price to Earnings Ratio|Company Value to Net Income ACHV (achievelifesciences.com)|Skye Bioscience (SKYE) - Price to Earnings Ratio|Price to Earnings Ratio Anebulo Pharmaceuticals Inc|INCR (InterCure Ltd) - P/E Multiple|Market Cap to Earnings Nutriband Corp NTRB|Price to Earnings Ratio Nasus Pharma Ltd (NSRX)|igcinc.us - Price to Earnings Multiple|Price to Earnings Ratio MIRA Pharmaceuticals, Inc. MIRA|Business Payback Period Flora Growth Corp (FLGC)|IMCC: Price to Earnings Ratio|Market Cap to Earnings Adial Pharmaceuticals|artelobio.com (ARTL) - Price to Earnings Ratio|TTNP - Business Payback Period|GNLN (Greenlane) - P/E Multiple|Price to Earnings Ratio InMed Pharmaceuticals Inc (INM)|P/E Multiple AKAN|ENVB - Market Cap to Earnings|Bright Green Corporation - Price to Earnings Ratio|Company Value to Net Income HPCO